Vallecillo, GabrielFonseca Casals, Francina, 1972-Oviedo, LinaDuran Jordà, Xavier, 1974-Martinez, IgnacioGarcía-Guix, AlexandraCastillo, ClaudioTorrens, MartaLlana, SantiagoRoquer, AlbertMartinez, Maria de la CabezaAguelo, SandraCanosa, IreneCOSG Group (COVID-19 and Opioids Study Group)2022-09-152022-09-152022Vallecillo G, Fonseca F, Oviedo L, Durán X, Martinez I, García-Guix A, Castillo C, Torrens M, Llana S, Roquer A, Martinez MC, Aguelo S, Canosa I; COSG Group (COVID-19 and Opioids Study Group). Similar COVID-19 incidence to the general population in people with opioid use disorder receiving integrated outpatient clinical care. Drug Alcohol Depend Rep. 2022 Mar;2:100027. DOI: 10.1016/j.dadr.2022.1000272772-7246http://hdl.handle.net/10230/54074Introduction: During the COVID-19 pandemic, limited access to health care augmented COVID-19 risk in subjects with opioid use disorder (OUD). The aim of the study was to compare COVID-19 incidence in individuals with OUD receiving continuous clinical care with that of the general population. Methods: A prospective cohort study was carried out from March 2020 to March 2021 comparing COVID-19 cumulative incidence of individuals presenting an OUD receiving integrated clinical care with that of an age-reference general population, in three public outpatient treatment centers for addiction in Barcelona, Spain. Results: Over the study period, 366 individuals received clinical care. Mean age: 48.2±8.9 years, 280 (76.5%) were men and 283 (77.3%) native Spanish. All subjects were on opioid agonist therapy. Prevalence of communicable diseases were: HIV infection in 109 (29.8%) and hepatitis C in 46 (12.6%). Psychiatric comorbidity was present in 207 (56.6%), and 119 (32.5%) had >1 chronic medical disease. Covid-19 was diagnosed in 10 patients: a cumulative incidence of 2,732 casesx100,000 people/year (C.I.95%: 1,318-4,967). There were no differences compared to the age-general population: 2,856 casesx100,000 people/year (C.I.95%: 2,830-2,880) (p=0.81). In the bivariate analysis, hypertension (5[50.0%] vs. 53[14.9%], p=0.01) and cardiovascular chronic diseases (2 [20.0%] vs. 8 [2.2%], p=0.03) were more prevalent in patients with OUD and COVID-19. Conclusions: Individuals with OUD who received integrated clinical care had a COVID-19 incidence comparable to the general population. Ensuring comprehensive healthcare is essential to prevent the clinical impact of COVID-19 on individuals with OUD.application/pdfeng© 2022 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Similar COVID-19 incidence to the general population in people with opioid use disorder receiving integrated outpatient clinical careinfo:eu-repo/semantics/articlehttp://dx.doi.org/10.1016/j.dadr.2022.100027info:eu-repo/semantics/openAccess